Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare ConferencesBusiness Wire • 09/08/20
Is the Options Market Predicting a Spike in Marinus (MRNS) Stock?Zacks Investment Research • 08/25/20
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial ResultsBusiness Wire • 08/06/20
Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Ganaxolone for the Treatment of CDKL5 Deficiency Disorder (CDD)Business Wire • 07/30/20
Marinus Pharmaceuticals to Present at SVB Leerink’s CybeRx Series: 2nd Annual CNS ForumGlobeNewsWire • 06/22/20
Marinus Pharmaceuticals Appoints Martha Manning as Vice President, General Counsel and SecretaryGlobeNewsWire • 06/15/20
Marinus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 06/02/20
Marinus Pharmaceuticals, Inc. (MRNS) CEO Scott Braunstein on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/04/20
Marinus Pharmaceuticals - Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 04/27/20
MARINUS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)GlobeNewsWire • 03/23/20
Marinus Pharmaceuticals Appoints Sasha Damouni Ellis as Vice President, Investor Relations and Corporate CommunicationsGlobeNewsWire • 03/19/20
Marinus Pharmaceuticals Completes Targeted Enrollment in Pivotal Phase 3 Study for CDKL5 Deficiency DisorderGlobeNewsWire • 02/25/20
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 02/14/20
Marinus Pharmaceuticals to Present at the 38th Annual J.P. Morgan Global Healthcare ConferenceGlobeNewsWire • 01/07/20